Zoetis (ZOE) Stock Price & Analysis
ZOE Stock Chart & Stats
- Day’s Range
- EUR 69.70 - EUR 72.00
- 52-Week Range
- EUR 61.16 - EUR 125.76
- Previous Close
- EUR 69.07
- Volume
- 759
- Average Volume (3M)
- 893
- Market Cap
- EUR 29.50B
- Enterprise Value
- EUR 37.58B
- Total Cash (Recent Filing)
- EUR 1.68B
- Total Debt (Recent Filing)
- EUR 9.24B
- Price to Earnings (P/E)
- 13.1
- Beta
- 0.62
- Next Earnings
- Nov 05, 2026 (Est.)
- EPS Estimate
- 1.35
- Last Dividend Ex-Date
- Oct 30, 2026
- Dividend Yield
- 2.57%
Bulls Say, Bears Say
Bulls Say
Strong Profitability And Cash Generation
High margins and substantial cash generation indicate a resilient, asset-light earnings model with strong conversion from profit to cash. This provides Zoetis with funding for research, product launches, acquisitions, dividends, and share repurchases while supporting durability through market cycles.
Diversified Growth Across Livestock, Diagnostics And International Markets
Growth is supported by multiple businesses and geographies rather than one narrow franchise. Livestock, diagnostics, international markets, and emerging-market demand can offset weakness in U.S. companion animals, improving portfolio resilience and sustaining future expansion.
Product Innovation And Regulatory Expansion
The Convenia RTU approval expands Zoetis’s treatment offering with a differentiated dosing format that may improve compliance and simplify care for owners and veterinarians. Regulatory approvals also extend the commercial life and strategic reach of the company’s portfolio.
Bears Say
Lowered 2026 Outlook
The reduced outlook signals that current operating pressure is material enough to affect full-year earnings, not merely quarterly results. Declining revenue and profit guidance can constrain near-term reinvestment capacity and indicate that recovery in core franchises may take time.
Companion Animal Weakness And Competitive Pressure
Weakness in the large companion-animal franchise creates a meaningful drag on the company’s growth profile. New entrants, discounting, rebates, and lower clinic visits may pressure market share and make revenue and margin recovery dependent on improved demand and execution.
Leverage Volatility And Reduced Equity Cushion
Historically elevated leverage and declining equity reduce the balance-sheet cushion available to absorb operational setbacks. The sharp difference between annual and TTM debt figures also makes leverage trends harder to interpret, limiting confidence in financial flexibility.
Zoetis News
ZOE FAQ
What was Zoetis’s price range in the past 12 months?
What is Zoetis’s market cap?
When is Zoetis’s upcoming earnings report date?
How were Zoetis’s earnings last quarter?
Is Zoetis overvalued?
Does Zoetis pay dividends?
What is Zoetis’s EPS estimate?
How many shares outstanding does Zoetis have?
What happened to Zoetis’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Zoetis?
What is the TipRanks Smart Score and how is it calculated?
Zoetis Stock Smart Score
Company Description
Zoetis
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
- Sector
- General
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Kristin C. Peck
- Employees
- 14,500
- Website
- www.zoetis.com
- Address
- 10 Sylvan Way, Parsippany, NJ, 07054, US
Zoetis (ZOE) Earnings & Revenues
ZOE Company Deck
ZOE Earnings Call
Earnings Call SentimentNegative
The call presented a mixed picture: clear strengths in Livestock, Diagnostics, international and continued pipeline progress, plus disciplined cost and capital return actions. However, material weakness in core Companion Animal markets—especially U.S. Dermatology and parasiticides—intensified competitive promotional activity, declining clinic visits, price realization pressure from gross-to-net investments, generics, and a meaningful downward revision to full-year guidance. While the portfolio diversification and cost actions provide resilience, the near-term trends in the company’s largest franchise create significant headwinds.
View all DE:ZOE earnings summariesZOE Net sales Breakdown
- 20.69% Vaccines
- 24.73% Parasiticides
- 18.53% Dermatology
- 10.94% Anti-infectives
- 8.87% Pain and sedation
- 7.36% Other pharmaceuticals
- 4.58% Animal health diagnostics
- 2.78% Other non-pharmaceuticals
- 0.29% Medicated feed additives
- 1.23% Contract manufacturing & human health
ZOE Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 13 | 6 | 3 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 10 | 0 | 2 |
